Site Language:

Site Language:

REGEN-006 Study Newsletter

Thank You for Helping Us Reach This Screening Milestone!

Screening Concluded on August 7, 2026!

We’re excited to announce that July broke the record for the study, with more than 100 participants screened!

Thank you for helping us reach this important study milestone.  In recent weeks, our trial sites have been working tirelessly to identify and screen participants, and we appreciate your tremendous effort through the final day of screening.  We especially value the patience of sites that have been with us since before the 2023 study pause and commend those who joined this year and immediately began screening. Your ongoing focus and perseverance have been crucial in the study’s success.

Please notify any patients who were previously contacted, screened, or pending re-screening that trial recruitment has now ended. If you have any questions about screening conclusion activities, please reach out to your ProKidney CTL.

Screening and Randomization Wind-Down

Your unwavering commitment has been essential to the study’s progress!

As we have previously communicated, the last day to screen a participant was Friday, August 7, 2026, and the last day to randomize will be Friday, November 6, 2026. The end dates for screening and randomization will help ensure that treatment/sham procedures are completed prior to the mid-2027 data readout.

Investigators and participants must remain blinded until the REGEN-006 study closure, projected to occur in the second half of 2029. All randomized participants must be followed, per protocol to ensure they attend their visits and remain in the study until their End-of-Study visit.

Your unwavering commitment to quality trial execution and patient care has been essential to the study’s progress, and we look forward to your continued partnership as we work toward study completion in 2029.

Adverse Event (AE) Reporting Reminders

In the Clinical Study Report, we will summarize the number of participants who experience each type of adverse event (AE). To ensure consistent AE terminology across study sites and enable accurate analysis of similar events, AE terms entered by sites are standardized using the MedDRA dictionary.

As part of this process, you may receive queries regarding AE terminology to help ensure events are coded, standardized, and counted appropriately. Common queries may include:

  • Please record each term on a separate log line.  MedDRA coding assumes one symptom/diagnosis per line, so terms such as “Redness and Swelling” should be recorded as two separate log lines as “Redness” and “Swelling” 
  • Please combine terms that represent signs and/or symptoms of a single diagnosis into one unifying diagnosis. Per the CRF Completion Guidelines, individual signs and symptoms that are attributable to a confirmed diagnosis should be reported under the diagnosis whenever possible. 
  • If a symptom is later determined to be part of an underlying diagnosis, please update the start date of the diagnosis to reflect the earliest onset date of any symptom that can be definitively attributed to that diagnosis.  Any individual symptoms covered by the overarching diagnosis should be inactivated in EDC. 
  • If an abnormal laboratory value is considered clinically significant, please record the diagnosis as the AE whenever possible rather than describing the laboratory abnormality itself (e.g., record “anemia” rather than “decreased hemoglobin”).

Additionally, CTCAE grading is used to standardize reporting of event severity.  The full CTCAE dictionary is available online. In general, CTCAE grades are defined according to the descriptions below.  If an event term and/or interventions given (or not given) do not appear consistent with the assigned CTCAE grade, you may receive a query.

  • Grade 1: Mild; asymptomatic or mild symptoms; clinical diagnostic observations only; intervention not indicated 
  • Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting instrumental ADL. 
  • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL 
  • Grade 4: Life-threatening consequences; urgent intervention indicated 
  • Grade 5: Death related to AE

Click here to visit the CTCAE Dictionary

Source documents for adjudication must be collected and submitted through the WCG AIMS Portal. Over 20 sites currently have outstanding uploads. Timely submission is critical, so endpoint adjudication can proceed as required by the protocol. Please ensure that you upload any outstanding source ASAP.  

Need help? AIMS portal issues: see the AIMS external user guide on Longboat or contact aimssupport@wcgclinical.com

Questions on the adjudication process: reach out to your PSI CRA and copy Marci.Parks@prokidney.com 

resources
for patients

Here’s information we’ve gathered to help you make the best decision for your health journey.

Rise to the top

Increase Sales

Lorem ipsum dolor sit amet, cons ctetur adiop iscing elit, sed do eiusmod tempor incid didunt ult labore et dolore magna aliqua ryuti dfyo jfko desr.

count on us

The ROI Experts

Lorem ipsum dolor sit amet, cons ctetur adiop iscing elit, sed do eiusmod tempor incid didunt ult labore et dolore magna aliqua ryuti dfyo jfko desr.

try, try again

Best Practices

Lorem ipsum dolor sit amet, cons ctetur adiop iscing elit, sed do eiusmod tempor incid didunt ult labore et dolore magna aliqua ryuti dfyo jfko desr.

Guidance on End of Treatment 

As we progress through the study, please remember that participants who do not complete all procedures should continue their study participation. This helps us capture important safety and efficacy data. Additionally, participants reaching transplant, dialysis, or specific kidney function milestones have abbreviated follow-up schedules. If you have any questions, please contact your PSI CRA or Medical Monitor.  

 

End of Treatment (EOT) 

  • Occurs when a participant receives either: 
  • Two rilparencel/sham injections (standard completion), OR 
  • One rilparencel/sham injection if they discontinued treatment early 
  • It does NOT mean the end of study participation 
  • If they don’t complete all procedures, encourage continued participation through Global Trial End Date (GTED) and transition to an abbreviated schedule (do not automatically withdraw).  

 

Reasons End of Treatment in EDC: 

  • Withdrawal by subject – participant is unable or unwilling to complete the treatment portion of the study (biopsy/sham or injection/sham)  
  • Pregnancy 
  • Withdrawal of consent – participant decides to stop his/her participation in the study and revokes consent.  
  • If this option is selected, End of Study form should also be completed. 
  • Physician Decision – If the decision is related to an adverse event, select Adverse Event instead. 
  • Adverse event – discontinuation due to any adverse event must be reflected in the AE form with ‘dose withdrawn’ selected as the action taken.   
  • Death  
  • Non-compliance with study schedule 
  • Sponsor Request – If the request is related to an adverse event, select Adverse Event instead. 
  • Lost to Follow-Up – the participant fails to return to the clinic for their scheduled visit and does not respond to attempts to contact. 
  • Protocol Deviation – Examples include, but are not limited to, randomization errors and/or enrollment of participants who do not meet eligibility criteria.  
  • Request for termination by sponsor or investigator – This option is no longer expected to be selected as a reason for termination.   
  • Physician Decision or Sponsor Request should be used in its place, as appropriate.  
  • Other, specify (free text) 
  • Note: If treatment is discontinued due to eGFR <15 and this is not clinically significant or reported as an AE, enter the following in the Other, specify field: “Discontinued for criteria eGFR <15 ml/min/1.73m2.” 

 

End of Study (EOS) 

  • Conducted at GTED or at time of early withdrawal 
  • MRI waived if completed within prior 6 months 
  • Should include all assessments in Schedule of Events when possible 

what is the impact of the proact 1 clinical trial?

Feel Free to Reach Out To Us!

Learn how we helped 100 top brands gain success.

Let's have a chat